Akinchan Bhardwaj: Key Genomic Insights Transforming Coronary Artery Disease Prevention
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent article by Heribert Schunkert et al, published in NEJM:
“For decades, we treated coronary artery disease as a consequence of lifestyle and conventional risk factors.
Genomics is rewriting that narrative.
A powerful new review in NEJM by Pradeep Natarajan and colleagues highlights a paradigm shift: coronary artery disease is not driven by a single genetic mutation or a single risk factor. Instead, most individuals inherit hundreds of genetic variants that collectively shape lifelong cardiovascular risk.
Some key insights that fundamentally change how we think about prevention:
- Monogenic disorders like familial hypercholesterolemia remain critical but explain only a small fraction of disease burden.
- Polygenic risk scores can identify individuals with a 3-5 fold higher lifetime risk of coronary artery disease; often decades before traditional clinical risk factors appear.
- Genetic risk is not deterministic. Lifestyle modification and lipid-lowering therapies appear to produce the greatest absolute benefit in individuals with the highest genetic risk.
- Many of our most effective cardiovascular therapies, including statins and PCSK9 inhibitors, emerged from understanding human genetic pathways.
Cardiology is gradually transitioning from reactive risk factor management toward biology-driven, lifetime precision prevention.
As our field advances, integrating genomics with clinical cardiology, imaging and interventional decision-making may redefine how we stratify risk and personalize therapy.
Outstanding review by Pradeep Natarajan, Herbert Schunkert and Nilesh Samani.”
Title: The Inherited Basis of Coronary Artery Disease
Authors: Heribert Schunkert, Pradeep Natarajan, Nilesh J. Samani
Read the Full Article on NEJM.
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia